TG Therapeutics
TGTX
376 hedge funds and large institutions have $3.9B invested in TG Therapeutics in 2025 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 118 increasing their positions, 118 reducing their positions, and 36 closing their positions.
133% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 36
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
33% more capital invested
Capital invested by funds: $2.92B → $3.9B (+$975M)
23% more call options, than puts
Call options by funds: $118M | Put options by funds: $96.4M
14% more funds holding
Funds holding: 331 → 376 (+45)
0.56% more ownership
Funds ownership: 62.41% → 62.97% (+0.56%)
0% more repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 118
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$38.7M |
| 2 |
ClearBridge Investments
New York
|
+$27.2M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$26.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$24M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$59.4M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$58M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$35.4M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$15.3M |
| 5 |
BlackRock
New York
|
-$13.6M |
TGTX Hedge Fund Activity: Q1 2025 in Review
376 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2025, worth a combined $3.9B — up 33% from $2.92B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new TGTX positions and 36 closed out — a net gain of 48 holders — while 118 added to existing stakes and 118 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $38.7M. The largest seller was State Street, cutting an estimated $59.4M.
- 376 institutional investors held TG Therapeutics (TGTX) as of Q1 2025, up from 331 in Q4 2024.
- Funds reported $3.9B of TG Therapeutics stock for Q1 2025, up 33% quarter-over-quarter.
- 84 funds opened new TG Therapeutics positions in Q1 2025 and 36 closed out, a net change of +48 holders.
- The largest TG Therapeutics buyer in Q1 2025 was Wellington Management Group, an estimated $38.7M added.
- The largest TG Therapeutics seller in Q1 2025 was State Street, an estimated $59.4M sold.
Based on aggregated 13F filings for Q1 2025.